Allakos Inc reports results for the quarter ended in March - Earnings Summary
Brief: Allakos Q1 Net Income USD -71.146 Million
Allakos Inc expected to post a loss of 47 cents a share - Earnings Preview
Allakos Inc reports results for the quarter ended in December - Earnings Summary
Brief: Allakos Q4 Net Income USD -62.551 Million
Allakos Inc expected to post a loss of 47 cents a share - Earnings Preview
Allakos Inc expected to post a loss of 47 cents a share - Earnings Preview
Brief: Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition
U.S. RESEARCH ROUNDUP-Burlington Stores, Carrols Restaurant Group, Mastec
U.S. STOCKS ON THE MOVE-Halozyme, Scorpio Tankers, Advanced Micro Devices
U.S. STOCKS ON THE MOVE-InMode, Carrols Restaurant, Tesla
Allakos down after lead skin disease drug fails studies
Allakos to stop further development of skin disease drug, plans job cuts (updated)
Allakos says experimental skin disease drug fails mid-stage studies
Brief: Allakos Announces Phase 2 Lirentelimab Trials In Atopic Dermatitis And Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints
Brief: Allakos Announces A Restructuring To Focus On Development Of Ak006
Brief: Allakos Files For Stock Shelf Of Up To $250 Mln - SEC Filing
Brief: Allakos Q3 Net Income USD -45.626 Million
Allakos Inc expected to post a loss of 45 cents a share - Earnings Preview